| アブストラクト | BACKGROUND: Rufinamide (RUF) is an antiepileptic drug recently introduced for managing seizures in Lennox-Gastaut syndrome (LGS), but its adverse reactions are not well understood. This study aims to evaluate RUF's safety profile using data from the FDA Adverse Event Reporting System (FAERS). METHODS: Disproportionality analysis was conducted to assess RUF-associated adverse drug events (ADEs), using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma-Poisson shrinker (MGPS). RESULTS: We collected 338 ADE reports related to RUF. Nervous system disorders were the most frequently reported signals, and several new ADEs were detected, including atonic seizures, sudden unexplained death in epilepsy, seizure clusters, multi-drug resistance, and Stevens-Johnson syndrome. Nearly half of the ADEs in pediatric patients were psychological or neurological. Disproportionality analysis within 4 weeks of treatment showed high RORs for QT shortening, sudden death, and atonic seizures. CONCLUSIONS: Our study revealed prospective signals of new ADEs linked to RUF as well as revealed that both prescribers and patients were more conscious of the risks involved in its clinical use. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| 投稿日 | 2024/10/9 |
|---|
| 投稿者 | Wang, Lingman; Gui, Jianxiong; Zhang, Xiaofang; Tian, Bing; Meng, Linxue; Liu, Jie; Jiang, Li |
|---|
| 組織名 | Department of Neurology, National Clinical Research Center for Child Health and;Disorders, Ministry of Education Key Laboratory of Child Development and;Disorders, Chongqing Key Laboratory of Pediatrics, Children's Hospital of;Chongqing Medical University, Chongqing, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39381902/ |
|---|
